Systematic reviews and a de novo model-based cost-utility analysis were used as economic evidence to support decision-making for the use of a bivalent RSV prefusion F protein–based (RSVpreF) vaccine and a long-acting monoclonal antibody (nirsevimab) in pregnant women and infants, respectively, for the prevention of RSV-related outcomes in the pediatric population. The systematic reviews are published (1, 2), and summarized below, along with an additional review of the grey literature. Details of the model-based cost-utility analysis are published elsewhere (3) . All costs are reported in 2023 Canadian dollars unless otherwise specified.

  • Background paper
  • Americas
  • Canada
  • RSV (Respiratory syncytial virus)